Welcome to The Visible Embryo

Home- - -History-- -Bibliography- -Pregnancy Timeline- --Prescription Drugs in Pregnancy- -- Pregnancy Calculator- --Female Reproductive System- News Alerts -Contact

Welcome to The Visible Embryo, a comprehensive educational resource on human development from conception to birth.

The Visible Embryo provides visual references for changes in fetal development throughout pregnancy and can be navigated via fetal development or maternal changes.

The National Institutes of Child Health and Human Development awarded Phase I and Phase II Small Business Innovative Research Grants to develop The Visible Embryo. Initally designed to evaluate the internet as a teaching tool for first year medical students, The Visible Embryo is linked to over 600 educational institutions and is viewed by more than ' million visitors each month.


WHO International Clinical Trials Registry Platform
The World Health Organization (WHO) has created a new Web site to help researchers, doctors and patients obtain reliable information on high-quality clinical trials. Now you can go to one website and search all registers to identify clinical trial research underway around the world!



Home

History

Bibliography

Pregnancy Timeline

Prescription Drug Effects on Pregnancy

Pregnancy Calculator

Female Reproductive System

Contact The Visible Embryo

News Alerts Archive

Disclaimer: The Visible Embryo web site is provided for your general information only. The information contained on this site should not be treated as a substitute for medical, legal or other professional advice. Neither is The Visible Embryo responsible or liable for the contents of any websites of third parties which are listed on this site.
Content protected under a Creative Commons License.

No dirivative works may be made or used for commercial purposes.

Return To Top Of Page
Pregnancy Timeline by SemestersFemale Reproductive SystemFertilizationThe Appearance of SomitesFirst TrimesterSecond TrimesterThird TrimesterFetal liver is producing blood cellsHead may position into pelvisBrain convolutions beginFull TermWhite fat begins to be madeWhite fat begins to be madeHead may position into pelvisImmune system beginningImmune system beginningPeriod of rapid brain growthBrain convolutions beginLungs begin to produce surfactantSensory brain waves begin to activateSensory brain waves begin to activateInner Ear Bones HardenBone marrow starts making blood cellsBone marrow starts making blood cellsBrown fat surrounds lymphatic systemFetal sexual organs visibleFinger and toe prints appearFinger and toe prints appearHeartbeat can be detectedHeartbeat can be detectedBasic Brain Structure in PlaceThe Appearance of SomitesFirst Detectable Brain WavesA Four Chambered HeartBeginning Cerebral HemispheresEnd of Embryonic PeriodEnd of Embryonic PeriodFirst Thin Layer of Skin AppearsThird TrimesterDevelopmental Timeline
Click weeks 0 - 40 and follow fetal growth
Search artcles published since 2007

July 9, 2012--------News Archive Return to: News Alerts


Breathing treatment for cystic fibrosis, using a mask nebulizer and a ThAIRapy Vest

WHO Child Growth Charts

       

DNA from Cystic Fibrosis Patients Reveals Unexpected Mutation

Comparing DNA from patients at the best and worst extremes of a health condition can reveal genes for resistance as well as weakness

A new approach reveals there are rare variations in the DCTN4 gene among cystic fibrosis patients who are most prone to early, chronic airway infections.


The DCTN4 gene codes for dynactin 4,
a protein which acts as part of a molecular motor
moving trouble-making microbes
along a cellular conveyer belt
into miniscule chemical vats,
called lysosomes, for annihilation.


The study, led by the University of Washington (UW), is part of the National Heart Lung and Blood Institute GO Exome Sequencing Project and its Lung GO, both major National Institutes of Health chronic disease research efforts.

Similar "testing the extremes" strategies may have important applications in uncovering genetic factors behind other more common, traits, such as healthy and unhealthy hearts. The results of the cystic fibrosis infection susceptibility study appeared July 8, as a letter in Nature Genetics.

The infectious agent was Pseudomonas aeruginosa, an opportunistic soil bacteria that commonly infects the lungs of people with cystic fibrosis and other airway-clogging disorders. This bacteria can unite into a slithery, hard-to-treat biofilm that harms lung tissue thus hampering breathing. Chronic infections are linked to poor lung function and shorter lives among cystic fibrosis patients. These bacteria rarely attack people with normal lungs and well-functioning immune systems.

In the study, the rare variations in DCTN4 did not appear in any cystic fibrosis patient who was resistant to Pseudomonas infection. Study subjects susceptible to early, chronic infection had at least one DCTN4 missense variant, meaning the protein will not function properly.

The patients selected for sequencing were from the Early Pseudomonas Control Observational Study (EPIC), a project at the Seattle Children's Research Institute, and the North American Cystic Fibrosis Genetic Modifiers Study. Exome sequencing was done by UW researchers in the laboratory of Deborah Nickerson, UW professor of genome sciences.

Statistical analysis of the DNA of 91 patients led the research team to DCTN4. Identification of the protein coding portions of these subjects' DNA called attention to missense variations in the DCTN4 gene. Researchers then screened a select group of 1,322 EPIC participants.

Exome Sequencing Project scientists are using an approach similar to the one used in EPIC to examine the genetics behind resistance and susceptibility to other chronic conditions such as obesity, heart attacks and hypertension. They will be looking for gene variations linked to heart disease, for example by comparing DNA maps of people with ideal cholesterol levels to those of people with exceptionally poor levels.

Adapting a similar strategy to determine the genetics underlying other complex human traits may require exome sequencing of much larger sample sizes, the researchers noted.


"As the costs of exome sequencing are dropping rapidly,
more efficient statistical analysis is becoming available;
we believe medical researchers' enthusiasm for this
approach will continue."

Michael Bamshad, PhD.


The lead author of the report is Mary J. Emond, research associate professor of biostatistics at the University of Washington School of Public Health in Seattle. The senior author is medical geneticist Michael Bamshad, UW professor of pediatrics in the Division of Genetic Medicine.

In addition to National Heart Lung and Blood Institute funding, the study released today was supported by grants from the National Human Genome Research Institute, the Cystic Fibrosis Foundation, and the Life Sciences Discovery Fund.

Original article: http://www.eurekalert.org/pub_releases/2012-07/uow-eso070612.php